USA – FDA grants fast track designation to AC Immune’s Alzheimer’s disease vaccine

The US Food and Drug Administration (FDA) has granted fast track designation to AC Immune SA’s investigational anti-amyloid beta immunotherapy vaccine for Alzheimer’s disease.

Par
RIS.WORLD
-

The candidate, ACI-24.060, will now benefit from the FDA’s fast track process, which is designed to improve the efficiency of product development and accelerate the review of treatments for serious conditions.

The announcement follows the FDA clearance of the company’s investigational new drug (IND) application, allowing for the expansion to the US of the ongoing phase 1b/2 ABATE study of ACI-24.060 in Alzheimer’s patients and individuals with Down’s syndrome…

ARTICLES CONNEXESPLUS DE L'AUTEUR